July 23 (Reuters) - Mesoblast Ltd (MSB) :
- FDA ACCEPTS MESOBLAST’S BIOLOGICS LICENSE APPLICATION (BLA) FOR RYONCIL® IN CHILDREN WITH STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (SR-AGVHD)
- MESOBLAST LTD - MESOBLAST ANTICIPATES A DECISION ON OR BEFORE FDA'S PRESCRIPTION DRUG USER FEE ACT (PDUFA) GOAL DATE OF JANUARY 7, 2025.
News: MSB FDA Accepts Mesoblast’S Biologics License Application For Ryoncil®
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.31 |
Change
0.150(13.0%) |
Mkt cap ! $1.490B | |||
| Open | High | Low | Value | Volume |
| $1.15 | $1.33 | $1.15 | $25.26M | 19.99M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 161000 | $1.30 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.31 | 50400 | 2 |
View Market Depth
| Last trade - 16.10pm 23/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |